A substantial $90.0M Series B round has landed for Spiko, the mobile software platform that transforms speech therapy into an engaging game for practicing target phonemes. The funding round saw participation from New Enterprise Associates (NEA) and Index Ventures, supporting Spiko's role as an intervention tool for phonological and articulation disorders. The platform is designed for both speech therapists and parents, offering a convenient way to continue speech sound practice at home.
Spiko Raises $90.0M
Get the full Spiko company profile
Access contacts, investors, buying signals & more
From the source
PaulToday we're announcing a $90 million Series B led by New Enterprise Associates (NEA), bringing Spiko's total funding to $120 million. Four months in, I am very proud of what this team has built, and of being part of it. What excites me most is what comes next.
Cash management has barely changed in decades: money market funds still run on business days, yield still depends on who you are and how much you hold, and a treasurer's options narrow quickly once you go beyond the overnight. We are working on a broader range of instruments for cash, built to give businesses and institutions a wider set of tools to choose from, with the same regulated setup and t
Other Greece companies recently funded
View all
Anacalypsis Therapeutics
"Anacalypsis" is the Greek word for Discovery. Our vision is a world in which neurodegenerative diseases are controllable, treatable, and curable. In most neurodegenerative diseases, including Parkinson's Disease, there are no disease-modifying therapies that can disrupt the progression of the disease. This is compounded by the fact that by the time diagnosis is made, significant irreversible neurodegeneration has already occurred. Parkinson’s disease is the fastest growing neurological disease, currently affecting approximately 10 million people globally. Similar to our approach for Parkinson's Disease, we are working on solving the unique challenges faced by people suffering from neurodegeneration by concurrently developing gene-based therapeutics and biomarkers. Our approach to therapeutic development is the structure-based design of compounds that disrupt specific protein interactions and signaling pathways that are linked to neurodegeneration.
$343.9K Pre-seed
14 days ago
Dataphoria
An Analytics-as-a-Service platform for any company, organization, or city who wants to measure, optimize and communicate its sustainability transition accurately and effectively.
Biggest recent Healthcare rounds
Largest funding rounds in Healthcare on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Kismet Australia | Pre-seed | $42.0B | 2y ago |
| 2 |  Johnson & Johnson United States | Unknown | $7.0B |
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  BackOps United States | Series b | $42.0M | today |
| 2 |  Levanta United States | Series b | $22.0M | today |
| 3 |
